Type 2 Diabetes Trial, Recruiting NCT06112418 Sponsor: Cleerly, Inc. Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Type 2 Diabetes Trial, Recruiting

NCT06112418
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have given their signed or electronic agreement to take part in the study
  • Men older than 55 years of age, or women older than 65 years of age
  • People who have been diagnosed with type 2 diabetes and are taking medication for it, or who have prediabetes (blood sugar levels slightly above normal but not yet in the diabetes range), or who have metabolic syndrome (a combination of 3 or more of the following: higher body weight or larger waist size; high triglycerides or treatment for them; low "good" cholesterol or treatment for it; raised blood pressure or treatment for it; or slightly elevated fasting blood sugar)
  • People who have access to a smartphone, tablet, or computer that can be used to communicate with the study's medical team

Who may not be able to join:

  • People who have a history of heart-related symptoms or events, such as a heart attack, chest pain during activity, stroke, leg artery problems, or a heart condition currently being managed by a heart specialist (such as irregular heartbeat or heart failure)
  • People who are scheduled to have a procedure to open or bypass a blocked artery
  • People whose kidneys do not filter blood well enough (below a certain level measured by a blood test) to safely receive the contrast dye used in the heart scan
  • People who have an allergy to the contrast dye used in scans, have had kidney damage from contrast dye in the past, or have signs of an untreated overactive thyroid
  • People who have had thyroid cancer in the past 5 years, or who are scheduled to have radioactive iodine treatment
  • People who weigh more than 300 pounds (136 kg) or above the weight limit of the scanner being used at the study site
  • People who are unable to hold their breath for more than 10 seconds (which is needed for the heart scan)
  • People who have an active irregular heartbeat that is not well controlled (heart rate above 80 beats per minute at the time of the scan)
  • People who cannot safely receive a beta blocker or nitroglycerin medication on the day of the heart scan
  • People where, in the study doctor's opinion, the heart scan is unlikely to produce a clear, usable result for any other reason
  • People considered unsuitable by the study doctor, including those found to have a severe narrowing of a major heart artery, those with a health condition that limits life expectancy to less than 3 years, or those considered unlikely to follow the study procedures (for example, due to active substance misuse or untreated mental illness that may affect participation)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Deepak Bhatt, MD, MPH, Mt. Sinai Heart

Phone: 7207398191

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Cleerly, Inc.
Registry
ClinicalTrials.gov
Start date
6 March 2024
Est. completion
5 March 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

The primary objective is to compare Cleerly stage-based care with risk factor-based care on the risk of CV events.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov